New combo therapy aims to silence hepatitis d in patients not helped by current drug
NCT ID NCT07128550
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 28 times
Summary
This study tests whether a combination of two experimental drugs (tobevibart and elebsiran) can clear hepatitis D virus from the blood of adults who still have active virus despite taking bulevirtide. About 150 participants aged 18–70 with compensated liver disease will receive the combo. The main goal is to see if the virus becomes undetectable after 24 weeks of treatment and stays undetectable 24 weeks after stopping.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VIRAL HEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigative Site
RECRUITINGInnsbruck, 6020, Austria
-
Investigative Site
RECRUITINGVienna, 1090, Austria
-
Investigative Site
RECRUITINGBobigny, 93009, France
-
Investigative Site
RECRUITINGClichy, 92110, France
-
Investigative Site
RECRUITINGCréteil, 94000, France
-
Investigative Site
RECRUITINGLe Chesnay, 78150, France
-
Investigative Site
RECRUITINGLimoges, 87000, France
-
Investigative Site
RECRUITINGLyon, 69004, France
-
Investigative Site
RECRUITINGMontpellier, 34295, France
-
Investigative Site
RECRUITINGPessac, 33604, France
-
Investigative Site
RECRUITINGRennes, 35033, France
-
Investigative Site
RECRUITINGToulouse, 31059, France
-
Investigative Site
RECRUITINGVillejuif, 94804, France
-
Investigative Site
RECRUITINGBerlin, 13353, Germany
-
Investigative Site
RECRUITINGEssen, 45147, Germany
-
Investigative Site
RECRUITINGFrankfurt am Main, 60590, Germany
-
Investigative Site
RECRUITINGHanover, 30625, Germany
-
Investigative Site
RECRUITINGBergamo, 24127, Italy
-
Investigative Site
RECRUITINGMilan, 20089, Italy
-
Investigative Site
RECRUITINGMilan, 20122, Italy
-
Investigative Site
RECRUITINGPisa, 56124, Italy
-
Investigative Site
RECRUITINGTorino, 10126, Italy
-
Investigative Site
RECRUITINGBucharest, 021105, Romania
-
Investigative Site
RECRUITINGBucharest, 022328, Romania
-
Investigative Site
RECRUITINGBucharest, 030303, Romania
-
Investigative Site
RECRUITINGCraiova, 200073, Romania
-
Investigative Site
RECRUITINGBarcelona, 08035, Spain
-
Investigative Site
RECRUITINGBarcelona, 08036, Spain
-
Investigative Site
RECRUITINGMadrid, 28007, Spain
-
Investigative Site
RECRUITINGMadrid, 28046, Spain
-
Investigative Site
RECRUITINGSantander, 39008, Spain
-
Investigative Site
RECRUITINGLondon, E1 1FR, United Kingdom
-
Investigative Site
RECRUITINGLondon, SE5 9NU, United Kingdom
-
Investigative Site
RECRUITINGLondon, W2 1NY, United Kingdom
-
Investigative Site
RECRUITINGManchester, M8 5RB, United Kingdom
-
Investigative Site
RECRUITINGNottingham, NG7 2UH, United Kingdom
Conditions
Explore the condition pages connected to this study.